High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas

Bone Marrow Transplantation

Volumn 39, Issue 8, 2007, Pages 471-476

  Yamada, K ^a   Takahashi, M ^a   Ogura, M ^a   Kagami, Y ^a   Taji, H ^a   Kamiya, Y ^a   Sugiura, H ^a   Morishima, Y ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EWING SARCOMA; FEASIBILITY STUDY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; LEUKOPENIA; MALE; MYELODYSPLASTIC SYNDROME; MYOCARDITIS; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SINGLE DRUG DOSE; SMALL CELL SARCOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; BONE NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SARCOMA, SMALL CELL; SOFT TISSUE NEOPLASMS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 34247236251     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705625     Document Type: Article

References (29)

1. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM et al. The Ewing family of tumors: A subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294-299.
2. Pisick E, Skarin AT, Salgia R. Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. Anticancer Res 2003; 23: 3379-3396.
3. Nesbit Jr ME, Gehan EA, Burgett Jr EO, Vietti TJ, Cangir A, Tefft M et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the first intergroup study. J Clin Oncol 1990; 8: 1664-1674.
4. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
5. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-3102.
6. Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20: 843-846.
7. Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, Bender-Gotze C et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 227-231.
8. Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000; 34: 328-337.
9. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Korholz D et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Ann Oncol 2000; 11: 1451-1462.
10. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001; 19: 870-880.
11. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewings sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812-2820.
12. Bertuzzi A, Castagna L, Nozza A, Quagliuolo V, Siracusano L, Balzarotti M et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study. J Clin Oncol 2002; 20: 2181-2188.
13. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71: 1904-1922.
14. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13: 610-630.
15. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyo-sarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group. J Clin Oncol 2006; 24: 3844-3851.
16. Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000; 18: 4-11.
17. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114.
18. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 2004; 42: 64-73.
19. Hawkins WG, Hoos A, Antonescu CR, Urist MJ, Leung DH, Gold JS et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 2001; 91: 794-803.
20. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 2003; 98: 571-580.
21. Little DJ, Ballo MT, Zagars GK, Pisters PW, Patel SR, El-Naggar AK et al. Adult rhabdomyosarcoma: Outcome following multimodality treatment. Cancer 2002; 95: 377-388.
22. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R et al. Localized Ewing tumor of bone: Final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001; 19: 1818-1829.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Engelhardt M, Zeiser R, Ihorst G, Finke J, Muller CI. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patients with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol 2006; 133: 1-11.
25. Laurence V, Pierga JY, Barthier S, Babinet A, Alapetite C, Palangie T et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am J Clin Oncol 2005; 28: 301-309.
26. Dunst J, Ahrens S, Paulussen M, Rube C, Winkelmann W, Zoubek A et al. Second malignancies after treatment for Ewing's sarcoma: A report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998; 42: 379-384.
27. Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A et al. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 2001; 12: 1619-1630.
28. Fuchs B, Valenzuela RG, Petersen IA, Arndt CA, Sim FH. Ewing's sarcoma and the development of secondary malignancies. Clin Orthop Relat Res 2003; 415: 82-89.
29. Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: A study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol 2006; 24: 3997-4002.